The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease

被引:7
|
作者
Mai, Huanzhuo [1 ,2 ]
Yang, Xing [1 ,2 ]
Xie, Yulan [1 ,2 ]
Zhou, Jie [1 ,2 ]
Wang, Qing [1 ,2 ]
Wei, Yiru [1 ,2 ]
Yang, Yuecong [1 ,2 ]
Lu, Dongjia [1 ,2 ]
Ye, Li [1 ,2 ,3 ]
Cui, Ping [2 ,3 ,4 ]
Liang, Hao [1 ,2 ,3 ,4 ]
Huang, Jiegang [1 ,2 ,5 ]
机构
[1] Guangxi Med Univ, Sch Publ Hlth, Nanning, Peoples R China
[2] Guangxi Med Univ, Guangxi Key Lab AIDS Prevent & Treatment, Nanning, Peoples R China
[3] Joint Lab Emerging Infect Dis China Guangxi ASEAN, Nanning, Peoples R China
[4] Guangxi Med Univ, Life Sci Inst, Nanning, Peoples R China
[5] Guangxi Med Univ, Guangxi Coll & Univ Key Lab Prevent & Control High, Nanning, Peoples R China
基金
中国国家自然科学基金;
关键词
gut microbiota; 16S ribosomal RNA gene amplicon sequencing; nonalcoholic fatty liver disease; liver disease; microbial markers; STEATOHEPATITIS;
D O I
10.3389/fmicb.2023.1257903
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background Non-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide, and gut microbes are associated with the development and progression of NAFLD. Despite numerous studies exploring the changes in gut microbes associated with NAFLD, there was no consistent pattern of changes.Method We retrieved studies on the human fecal microbiota sequenced by 16S rRNA gene amplification associated with NAFLD from the NCBI database up to April 2023, and re-analyzed them using bioinformatic methods.Results We finally screened 12 relevant studies related to NAFLD, which included a total of 1,189 study subjects (NAFLD, n = 654; healthy control, n = 398; obesity, n = 137). Our results revealed a significant decrease in gut microbial diversity with the occurrence and progression of NAFLD (SMD = -0.32; 95% CI -0.42 to -0.21; p < 0.001). Alpha diversity and the increased abundance of several crucial genera, including Desulfovibrio, Negativibacillus, and Prevotella, can serve as an indication of their predictive risk ability for the occurrence and progression of NAFLD (all AUC > 0.7). The occurrence and progression of NAFLD are significantly associated with higher levels of LPS biosynthesis, tryptophan metabolism, glutathione metabolism, and lipid metabolism.Conclusion This study elucidated gut microbes relevance to disease development and identified potential risk-associated microbes and functional pathways associated with NAFLD occurrence and progression.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
    Han, Ruiting
    Ma, Junli
    Li, Houkai
    FRONTIERS OF MEDICINE, 2018, 12 (06) : 645 - 657
  • [42] Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease
    Bakhshimoghaddam, Farnush
    Alizadeh, Mohammad
    HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (02) : 223 - 226
  • [43] Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
    Tang, Ruiqi
    Liu, Rongrong
    Zha, Hua
    Cheng, Yiwen
    Ling, Zongxin
    Li, Lanjuan
    ENGINEERING IN LIFE SCIENCES, 2024, 24 (05):
  • [44] Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
    Demir, Muenevver
    Lang, Sonja
    Martin, Anna
    Farowski, Fedja
    Wisplinghoff, Hilmar
    Vehreschild, Maria J. G. T.
    Krawczyk, Marcin
    Nowag, Angela
    Scholz, Claus Jurgen
    Kretzschmar, Anne
    Roderburg, Christoph
    Lammert, Frank
    Goeser, Tobias
    Kasper, Philipp
    Steffen, Hans-Michael
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (11) : 1969 - 1977
  • [45] Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
    Ruiting Han
    Junli Ma
    Houkai Li
    Frontiers of Medicine, 2018, 12 : 645 - 657
  • [46] Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Non-alcoholic Fatty Liver Disease
    Ralli, Tanya
    Neupane, Yub Raj
    Saifi, Zoya
    Kohli, Kanchan
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (46) : 4677 - 4685
  • [47] Mechanisms behind the Role of SIBO in Non-Alcoholic Fatty Liver Disease: An Interplay between Liver, Gut Microbiota and Nutrition
    Yigit, Asli
    Samur, Gulhan
    CURRENT NUTRITION & FOOD SCIENCE, 2023, 19 (02) : 84 - 93
  • [48] Angiogenesis in the progression of non-alcoholic fatty liver disease
    Lefere, S.
    Devisscher, L.
    Geerts, A.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2020, 83 (02) : 301 - 307
  • [49] Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota?
    Knaapen, M.
    Kootte, R. S.
    Zoetendal, E. G.
    de Vos, W. M.
    Dallinga-Thie, G. M.
    Levi, M.
    Stroes, E. S.
    Nieuwdorp, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (04) : 331 - 337
  • [50] Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease
    Giulia Paolella
    Claudia Mandato
    Luca Pierri
    Marco Poeta
    Martina Di Stasi
    Pietro Vajro
    World Journal of Gastroenterology, 2014, 20 (42) : 15518 - 15531